Patents by Inventor Shaomeng Wang

Shaomeng Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
    Patent number: 10829488
    Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b E, and = are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: November 10, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Jianyong Chen
  • AMINOPYRIMIDINES AS ALK INHIBITORS
    Publication number: 20200330464
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
    Type: Application
    Filed: June 29, 2020
    Publication date: October 22, 2020
    Inventors: Shaomeng Wang, Jianyong Chen
  • 5,6-dihydro-11H-indolo[2,3-B]quinolin-11-ones as alk inhibitors
    Patent number: 10781208
    Abstract: The present disclosure provides compounds represented by Formula (I), and the pharmaceutically acceptable salts and solvates thereof wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, E and (B) are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: September 22, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jianyong Chen, Liu Liu, Xuyuan Dong, Chao-Yie Yang, Donna McEachern, Shaomeng Wang
  • BET Bromodomain Protein Degraders with Cleavable Linkers
    Publication number: 20200277305
    Abstract: The present disclosure provides compounds represented by Formula (I): Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3a, R3b, R4, Y, ?, Ar, W, L, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I)I for use to treat a condition or disorder responsive to inhibition and/or degradation of BET bromodomains such as cancer.
    Type: Application
    Filed: September 12, 2018
    Publication date: September 3, 2020
    Inventors: Shaomeng Wang, Weiguo Xiang, Fuming Xu, Longchuan Bai, Ester Fernandez-Salas, Donna McEachern
  • Monofunctional intermediates for ligand-dependent target protein degradation
    Patent number: 10759808
    Abstract: The present disclosure provides compounds represented by Formula I: and the salts or solvates thereof, wherein X, L, Y, and B are as defined in the specification. Compounds having Formula I are immunomodulators and/or monofunctional synthetic intermediates that can be used to prepare small-molecule drug conjugates.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: September 1, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yangbing Li, Angelo Aguilar, Bing Zhou, Jiantao Hu, Fuming Xu, Chong Qin, Yang Hu, Weiguo Xiang, Rohan Rej, Jiuling Yang, Xin Han, Longchuan Bai, Chao-Yie Yang
  • Aminopyrimidines as ALK inhibitors
    Patent number: 10709705
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
    Type: Grant
    Filed: August 28, 2017
    Date of Patent: July 14, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Jianyong Chen
  • PYRROLO[2,3-C]PYRIDINES AND RELATED ANALOGS AS LSD-1 INHIBITORS
    Publication number: 20200157091
    Abstract: The present disclosure provides compounds represented by Formula I and II: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, X, W, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I and II for use to treat a condition or disorder responsive to LSD1 inhibition such as cancer.
    Type: Application
    Filed: May 15, 2018
    Publication date: May 21, 2020
    Inventors: Shaomeng Wang, Dengyou Zhang, Canhui Zheng, Zhuo Chen, Liu Liu, Liyue Huang, Chao-Yie Yang
  • BET protein degraders
    Patent number: 10633386
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein B, R1, R5, Q1, Q?, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: April 28, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Bing Zhou, Fuming Xu, Jiantao Hu, Longchuan Bai, Chao-Yie Yang
  • SMALL MOLECULE MDM2 PROTEIN DEGRADERS
    Publication number: 20200109149
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R1a, R1b, R2a, R2b, R3a, R3b, R4, A, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to degradation of MDM2 protein.
    Type: Application
    Filed: October 7, 2019
    Publication date: April 9, 2020
    Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Angelo Aguilar, Yangbing Li, Jiuling Yang, Donna McEachern
  • SMALL MOLECULE DCN1 INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
    Publication number: 20200109167
    Abstract: Compounds of formula (I) as inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 9, 2020
    Inventors: Shaomeng Wang, Haibin Zhou, Jianfeng Lu, Liu Liu, Yi Sun, Denzil Bernard
  • PIPERIDINES AS COVALENT MENIN INHIBITORS
    Publication number: 20200022953
    Abstract: The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Application
    Filed: March 30, 2018
    Publication date: January 23, 2020
    Inventors: Shaomeng Wang, Angelo Aguilar, Shilin Xu, Liyue Huang, Jeanne Stuckey, Tianfeng Xu
  • Fused 1,4-Diazepines as BET Bromodomain Inhibitors
    Publication number: 20190382415
    Abstract: The present disclosure provides fused 1,4-diazepines represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A. E, R1, R2, R3, R4, R5, and Ar are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds having Formula (I) to treat diseases, conditions, or disorders responsive to inhibition of BET bromodomain proteins such as cancer.
    Type: Application
    Filed: February 2, 2018
    Publication date: December 19, 2019
    Inventors: Shaomeng Wang, Jiantao Hu, Fuming Xu
  • Covalent small molecule DCN1 inhibitors and therapeutic methods using the same
    Patent number: 10500194
    Abstract: Small molecule covalent inhibitors of DCN1 and compositions containing the same are disclosed. Methods of using the DCN1 covalent inhibitors in the treatment of diseases and conditions wherein inhibition of DCN1 provides a benefit, like oxidative stress-related diseases and conditions, neurodegenerative diseases and conditions, metabolic disorders, and muscular nerve degeneration, also are disclosed.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: December 10, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Haibin Zhou, Jianfeng Lu, Liu Liu, Jeanne Stuckey, Liangyou Rui, Yi Sun
  • N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS
    Publication number: 20190315739
    Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b E, and = are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.
    Type: Application
    Filed: August 4, 2017
    Publication date: October 17, 2019
    Inventors: Shaomeng Wang, Jianyong Chen
  • 5,6-DIHYDRO-11H-INDOLO[2,3-B]QUINOLIN-11-ONES AS ALK INHIBITORS
    Publication number: 20190315741
    Abstract: The present disclosure provides compounds represented by Formula (I), and the pharmaceutically acceptable salts and solvates thereof wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, R7, E and (B) are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
    Type: Application
    Filed: November 17, 2017
    Publication date: October 17, 2019
    Inventors: Jianyong Chen, Liu Liu, Xuyuan Dong, Chao-Yie Yang, Donna McEachern, Shaomeng Wang
  • FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS
    Publication number: 20190263827
    Abstract: The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
    Type: Application
    Filed: September 13, 2017
    Publication date: August 29, 2019
    Inventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Weiguo Xiang, Bing Zhou
  • BET bromodomain inhibitors and therapeutic methods using the same
    Patent number: 10391175
    Abstract: Inhibitors of BET bromodomains and compositions containing the same are disclosed. Methods of using the BET bromodomain inhibitors in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, also are disclosed.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: August 27, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Xu Ran, Yujun Zhao, Chao-Yie Yang, Liu Liu, Longchuan Bai, Donna McEachern, Jeanne Stuckey, Jennifer Lynn Meagher, Duxin Sun, Xiaoqin Li, Bing Zhou, Hacer Karatas, Ruijuan Luo, Arul Chinnaiyan, Irfan A. Asangani
  • AMINOPYRIMIDINES AS ALK INHIBITORS
    Publication number: 20190175595
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
    Type: Application
    Filed: August 28, 2017
    Publication date: June 13, 2019
    Inventors: Shaomeng WANG, Jianyong CHEN
  • BET PROTEIN DEGRADERS
    Publication number: 20190169195
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein B, R1, R5, Q1, Q?, L, X, Y, and Z are as defined as set forth in the specification. The present disclosure also provids compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
    Type: Application
    Filed: April 6, 2017
    Publication date: June 6, 2019
    Inventors: Shaomeng Wang, Bing Zhou, Fuming Xu, Jiantao Hu, Longchuan Bai, Chao-Yie Yang
  • 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
    Patent number: 10307407
    Abstract: The present disclosure provides substituted 9H-pyrimido [4,5-b] indoles and 5H-pyrido [4,3-b] indoles and related analogs represented by Formula I and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, W, B1, B2, G, X1, Y1, Y2, and Y3 are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains such as cancer. The present disclosure is also directed to the use of compound of Formula I as synthetic intermediates.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: June 4, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yujun Zhao, Bing Zhou, Angelo Aguilar